Market
What will be Datroway's market penetration in the US for HR-positive, HER2-negative advanced breast cancer by the end of 2025?
2
Resolution / Starting Odds
Less than 20% • 25%
20-40% • 25%
40-60% • 25%
More than 60% • 25%
Market research reports and sales data
Story
AstraZeneca and Daiichi Sankyo's Datroway Approved by FDA for HR-Positive, HER2-Negative Advanced Breast Cancer Based on Phase III Trial
Jan 21, 2025, 12:00 PM
AstraZeneca and Daiichi Sankyo have received U.S. Food and Drug Administration (FDA) approval for their drug Datroway (datopotamab deruxtecan, or Dato-DXd) for the treatment of adults with previously treated, unresectable, or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The approval is based on the results of the TROPION-Breast01 Phase III trial, which showed a significant reduction in the risk of disease progression or death compared to chemotherapy. Datroway targets TROP2, a protein found on many cancer cells, and represents a new treatment option for patients who have progressed after endocrine-based therapy and chemotherapy. The drug is administered intravenously at a dose of 6 mg/kg once every 21 days. Daiichi Sankyo's stock rose the most in five months following the approval, reflecting the market's positive reception of this milestone in the company's efforts to develop a widely used blockbuster treatment.
View original story
Similar markets
No • 50%
Yes • 50%
10% to 20% • 25%
20% to 30% • 25%
Less than 10% • 25%
More than 30% • 25%
10% to 20% • 25%
More than 30% • 25%
Less than 10% • 25%
20% to 30% • 25%
More than 15% • 25%
Less than 5% • 25%
10% to 15% • 25%
5% to 10% • 25%
20% to 40% • 25%
Less than 20% • 25%
More than 60% • 25%
40% to 60% • 25%
Yes • 50%
No • 50%
More than two • 25%
Two • 25%
One • 25%
None • 25%
Fewer than 30 countries • 25%
30 to 60 countries • 25%
60 to 90 countries • 25%
More than 90 countries • 25%
Yes • 50%
No • 50%
Europe • 25%
Other • 25%
North America • 25%
Asia • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
Roche • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%